Richard Law
Stock Analyst at Goldman Sachs
(0)
# 4473
Out of 5,231 analysts
55
Total ratings
29.17%
Success rate
-12.11%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
MoonLake | Upgrades: Buy | 62 82 | 46.12 | 77.8% | 2 | Jan 17, 2025 | |
Celldex Therapeutics | Initiates Coverage On: Neutral | 45 | 25.59 | 75.85% | 1 | Sep 30, 2024 | |
Viridian Therapeutic... | Maintains: Strong Buy | 25 31 | 19.46 | 59.3% | 2 | Sep 12, 2024 | |
Mineralys Therapeuti... | Initiates Coverage On: Buy | 30 | 10.38 | 189.02% | 5 | Apr 2, 2024 | |
Olema Pharmaceutical... | Initiates Coverage On: Buy | 24 | 6.2 | 287.1% | 4 | Apr 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 39 | 10.42 | 274.28% | 1 | Apr 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 11 | 5.9 | 86.44% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 31 | 7.7 | 302.6% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 46 47 | 25.95 | 81.12% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 62 63 | 41.25 | 52.73% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 36 37 | 39.3 | -5.85% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 76 | 10.15 | 648.77% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 36 | n/a | n/a | 4 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 15 14 | 1.34 | 944.78% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 61 | 17.65 | 245.61% | 4 | May 8, 2023 |